BUSINESSSCMP WORLD
Cross-border biotech deals grow more complex as US targets China investment links
Cross-border biotech deals between China and the United States are becoming more complex as the U.S. targets investment links, leading to potential slowdowns, according to analysts. Diederik Stadig of ING Research noted increased geopolitical scrutiny may result in fewer deals.
Mentioned
Related Signal
Adjacent reporting
- Cross-border biotech deals grow more complex as US targets China investment links
- The next tech war? Why biotech may become a new US-China battleground
- China's biotech boom alarms Western lawmakers, investors
- STAT+: Pharmalittle: We’re reading about U.S. biotech’s China problem, a Regeneron flop, and much more
- Growing US reliance on Chinese biotechs prompts national security fears
- China’s biotech industry sees global expansion as unstoppable, despite US pressure